Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust ...
StockStory.org on MSN
DexCom (DXCM) stock trades down, here is why
What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...
The average one-year price target for DexCom (BIT:1DXCM) has been revised to €77.53 / share. This is a decrease of 12.39% from the prior estimate of €88.50 dated November 9, 2025. The price target is ...
Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...
In addition to Canaccord Genuity, Dexcom also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Barclays reiterated a Sell rating on Dexcom (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback